AI u medicini dijagnoza: što algoritam vidi, a što propušta

Dokumentarac prati kako AI dijagnostički sustav IDx-DR donosi klinički zaključak za 20 sekundi u ordinaciji obiteljske medicine, bez prisutnosti oftalmologa. Uspoređuje ga s Epic modelom sepse čija je neovisna validacija pokazala AUC 0,63 i propuštanje 67% slučajeva sepse, te s randomiziranom studijom MASAI koja je otkrila 44% manje radiologa potrebnih za čitanje mamografija. Gledatelj odlazi s dokumentiranim granicama svake od ovih primjena: što je potvrđeno prospektivnim ispitivanjima, a što ostaje otvoreno. Poglavlja 00:00 Dvadeset sekundi 01:56 Dijagnostička praznina 05:58 Stroj koji uči na milijunima snimki 09:44 IDx-DR: prvo autonomno odobrenje 14:40 Kad alarm laže: Epic i sepsa 19:03 Randomizirana studija: MASAI u Švedskoj 23:04 Tko dobiva, tko plaća i što ostaje otvoreno 30:49 Isti ekran, drugačija pitanja Izvori - npj Digital Medicine; Medicine Iowa (University of Iowa Health Care magazine) — Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices; Running IDx through its trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC6550188/ - npj Digital Medicine (Nature Publishing Group) — Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices: https://pmc.ncbi.nlm.nih.gov/articles/PMC6550188/ - FDA / PRNewswire — FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems: https://www.prnewswire.com/news-releases/fda-permits-marketing-of-artificial-intelligence-based-device-to-detect-certain-diabetes-related-eye-problems-300628218.html - U.S. Food and Drug Administration (FDA) — Device Classification Under Section 513(f)(2)(De Novo) — DEN180001: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?ID=DEN180001 - Diabetes Research and Clinical Practice / International Diabetes Federation — IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045: https://www.sciencedirect.com/science/article/abs/pii/S0168822721004782 - Ophthalmology (American Academy of Ophthalmology) — Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis: https://www.aaojournal.org/article/S0161-6420(21)00321-3/abstract - Seminars in Ophthalmology (Taylor & Francis) — Global and Regional Prevalence of Diabetic Retinopathy; A Comprehensive Systematic Review and Meta-analysis: https://www.tandfonline.com/doi/full/10.1080/08820538.2021.1962920 - Journal of Clinical Medicine / PubMed Central — Social Determinants of Health and Impact on Screening, Prevalence, and Management of Diabetic Retinopathy in Adults: A Narrative Review: https://pmc.ncbi.nlm.nih.gov/articles/PMC9739502/ - PubMed Central / multiple citing sources — Diabetic Retinopathy and Eye Screening: Diabetic Patients Standpoint, Their Practice, and Barriers; A Cross-Sectional Study (citing Nwanyanwu et al. 2018, Yale School of Medicine, J Clin Transl Sci): https://pmc.ncbi.nlm.nih.gov/articles/PMC9654427/ - IAPB Vision Atlas / AJO International (Resnikoff et al., 2026;3:100260) — The global eye care workforce: 2023 estimates across ophthalmologists, optometrists, and allied personnel: https://visionatlas.iapb.org/news/global-eye-care-workforce-2023-estimates-released/ - U.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH) — De Novo Classification Request – IDx-DR (DEN180001): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN180001 - Bipartisan Policy Center — FDA Oversight: Understanding the Regulation of Health AI Tools: https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/ - U.S. Code of Federal Regulations via Cornell Law School Legal Information Institute — 21 CFR § 886.1100 – Retinal diagnostic software device: https://www.law.cornell.edu/cfr/text/21/886.1100 - Quandary Peak / U.S. FDA — Clinical Decision Support Software – FDA Final Guidance (analysis): https://quandarypeak.com/2022/12/fda-releases-final-guidance-on-clinical-decision-support-software-as-a-medical-device/ - Quandary Peak (analysis of FDA September 2022 guidance); primary guidance at FDA.gov — FDA Releases Final Guidance on Clinical Decision Support Software as a Medical Device: https://quandarypeak.com/2022/12/fda-releases-final-guidance-on-clinical-decision-support-software-as-a-medical-device/ - PMC / MDPI — Detection of Diabetic Retinopathy using Convolutional Neural Networks for Feature Extraction and Classification (DRFEC): https://pmc.ncbi.nlm.nih.gov/articles/PMC9708148/ - … Napomene - Naracija: sintetski (AI) glas. Glazba: originalna, sintetizirana za ovaj video. - Sheme su pojednostavljeni prikazi. #dokumentarac #AIuMedicini #digitalnozdravlj

Pogledaj na YouTubeu